Literature DB >> 8806978

Effect of acute and chronic losartan treatment on glucose tolerance and insulin sensitivity in fructose-fed rats.

S N Iyer1, M J Katovich.   

Abstract

The purpose of this study was to evaluate the role of angiotensin II (AII) in fructose-treated rats by assessing the effects of acute and chronic losartan treatment on glucose tolerance and insulin sensitivity. The effect of acute losartan treatment was assessed on blood glucose and serum insulin profiles during an intravenous glucose tolerance test (IVGTT) in control and fructose-fed rats. Acute losartan treatment was effective in lowering both blood glucose and plasma insulin profiles in fructose-treated rats during the IVGTT compared to the saline-injected fructose-treated rats. In a subsequent study, 2 weeks after chronic fructose and losartan treatment, IVGTT were performed. Chronic losartan treatment also improved both the glucose tolerance and insulin sensitivity in fructose-treated rats. Additionally chronic losartan treatment also was effective in blocking the hyperinsulinemia, hypertension, and cardiac hypertrophy observed in fructose-fed rats. In neither acute nor chronic studies were there any effects of losartan in control animals. These results strongly suggest that the renin-angiotensin system modulates the insulin resistance, hypertension, and cardiac hypertrophy in fructose-treated rats.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8806978     DOI: 10.1016/0895-7061(96)00035-0

Source DB:  PubMed          Journal:  Am J Hypertens        ISSN: 0895-7061            Impact factor:   2.689


  13 in total

1.  The effect of losartan and carvedilol on renal haemodynamics and altered metabolism in fructose-fed Sprague-Dawley rats.

Authors:  Mohammed H Abdulla; Munavvar A Sattar; Nor A Abdullah; Edward J Johns
Journal:  J Physiol Biochem       Date:  2012-01-27       Impact factor: 4.158

2.  Cardiovascular interactions between losartan and fructose in mice.

Authors:  Danielle Senador; Mary Key; K Bridget Brosnihan; Maria Claudia Irigoyen; Khalid M Elased; Mariana Morris
Journal:  J Cardiovasc Pharmacol Ther       Date:  2009-12-07       Impact factor: 2.457

3.  Vascular smooth muscle insulin resistance, but not hypertrophic signaling, is independent of angiotensin II-induced IRS-1 phosphorylation by JNK.

Authors:  Hirofumi Hitomi; Puja K Mehta; Yoshihiro Taniyama; Bernard Lassègue; Bonnie Seidel-Rogol; Alejandra San Martin; Kathy K Griendling
Journal:  Am J Physiol Cell Physiol       Date:  2011-09-07       Impact factor: 4.249

4.  Cardiovascular and autonomic phenotype of db/db diabetic mice.

Authors:  Danielle Senador; Keerthy Kanakamedala; Maria Claudia Irigoyen; Mariana Morris; Khalid M Elased
Journal:  Exp Physiol       Date:  2009-02-13       Impact factor: 2.969

5.  Comparative effects of lisinopril and losartan on insulin sensitivity in the treatment of non diabetic hypertensive patients.

Authors:  R Fogari; A Zoppi; L Corradi; P Lazzari; A Mugellini; P Lusardi
Journal:  Br J Clin Pharmacol       Date:  1998-11       Impact factor: 4.335

Review 6.  The fructose-fed rat: a review on the mechanisms of fructose-induced insulin resistance and hypertension.

Authors:  Linda T Tran; Violet G Yuen; John H McNeill
Journal:  Mol Cell Biochem       Date:  2009-06-18       Impact factor: 3.396

7.  Endothelin-1 modulates angiotensin II in the development of hypertension in fructose-fed rats.

Authors:  L T Tran; K M MacLeod; J H McNeill
Journal:  Mol Cell Biochem       Date:  2009-01-13       Impact factor: 3.396

8.  Dietary fructose enhances angiotensin II-stimulated Na+ transport via activation of PKC-α in renal proximal tubules.

Authors:  Nianxin Yang; Nancy J Hong; Jeffrey L Garvin
Journal:  Am J Physiol Renal Physiol       Date:  2020-05-11

9.  Aliskiren prevents and ameliorates metabolic syndrome in fructose-fed rats.

Authors:  Chu-Lin Chou; Yu-Hsien Lai; Teng-Yi Lin; Tony J F Lee; Te-Chao Fang
Journal:  Arch Med Sci       Date:  2011-11-08       Impact factor: 3.318

10.  Randomized placebo-controlled trial of losartan for pediatric NAFLD.

Authors:  Miriam B Vos; Mark L Van Natta; Niviann M Blondet; Srinivasan Dasarathy; Mark Fishbein; Paula Hertel; Ajay K Jain; Saul J Karpen; Joel E Lavine; Saeed Mohammad; Laura A Miriel; Jean P Molleston; Marialena Mouzaki; Arun Sanyal; Emily P Sharkey; Jeffrey B Schwimmer; James Tonascia; Laura A Wilson; Stavra A Xanthakos
Journal:  Hepatology       Date:  2022-02-28       Impact factor: 17.298

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.